Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Aliqopa (copanlisib) for the Treatment of Relapsed Follicular Lymphoma

Drug (Brand / Generic)

Aliqopa / copanlisib

Developer

Bayer

Therapy Class

Phosphatidylinositol-3-kinase (PI3K) inhibitor

Current Indication

Follicular lymphoma

Market Sector

Oncology

Development Status

Approved in the US
Expand

Go Top